However, because select serotonin-reuptake inhibitors (SSRIs) and serotonin - norepinephrine reuptake inhibitors (SNRIs) have anti-inflammatory properties, these drugs are hypothesized to ameliorate the inflammatory state accompanying COVID-19 as well as the co-existing depressive disorder.